Pharmacological management of diabetes in severe mental illness: a comprehensive clinical review of efficacy, safety and tolerability

Expert Review of Clinical Pharmacology
John LallyFiona Gaughran

Abstract

The increased prevalence of Type 2 diabetes mellitus (T2DM) in severe mental illness (SMI) contributes to increased cardiovascular morbidity and reduced life expectancy for people with SMI. Areas covered: In the present clinical review, we summarize the efficacy, safety and tolerability of selected diabetic pharmacotherapy options in SMI and discuss the quality and strength of evidence. Expert commentary: General principles for treating T2DM in SMI involve identifying treatments which promote weight loss and which have low or no risk of hypoglycemia. Patient engagement in decision making about treatment choices is an important factor to ensure adherence and successful use of the chosen therapy. The first line therapeutic option for T2DM in SMI for which there is most evidence is metformin. Based on general population data, second line treatment options in combination with metformin to achieve glycated haemoglobin treatment goals include GLP-1R agonists, DPP-4 inhibitors, sulphonylureas, SGLT2 inhibitors, pioglitazone and insulin, with most evidence for the use of GLP-1R agonists in SMI. Alongside efficacy and tolerability, treatment for T2DM in SMI should be considered on a patient-tailored basis.

References

Mar 1, 1996·Schizophrenia Research·C M GilvarryR M Murray
Feb 8, 2002·The New England Journal of Medicine·William C KnowlerUNKNOWN Diabetes Prevention Program Research Group
Feb 3, 2004·The American Journal of Psychiatry·Oliver D HowesLyn S Pilowsky
Mar 27, 2007·Diabetic Medicine : a Journal of the British Diabetic Association·L M SpelmanJ H Thakore
Feb 12, 2008·The American Journal of Medicine·Shelley R SalpeterEdwin E Salpeter
Jun 2, 2009·The American Journal of Medicine·David M KendallRichard M Bergenstal
Sep 29, 2009·European Psychiatry : the Journal of the Association of European Psychiatrists·M BernardoUNKNOWN RICAVA Study Group
Jun 4, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jimmi NielsenChristoph U Correll
Jul 20, 2010·Diabetes Care·Darin E OlsonLawrence S Phillips
Sep 14, 2010·Schizophrenia Research·P I Lin, A R Shuldiner
Oct 5, 2010·The British Journal of Psychiatry : the Journal of Mental Science·Lars Vedel KessingPer Kragh Andersen
Feb 3, 2011·British Journal of Clinical Pharmacology·Samir Kumar PraharajVinod Kumar Sinha
Mar 8, 2011·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Marc DE HertStefan Leucht
Nov 29, 2011·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Barbara ZaniniAlberto Lanzini
Nov 17, 2012·Journal of Psychiatric Research·Salvatore DipasqualeValeria Mondelli
Jul 13, 2013·The American Journal of Psychiatry·L Fredrik JarskogUNKNOWN METS Investigators
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 13, 2013·Annals of Internal Medicine·Despoina VasilakouApostolos Tsapas
Sep 26, 2013·Schizophrenia Research·Matthieu CrewsFiona Gaughran
Feb 11, 2014·Diabetes Research and Clinical Practice
Feb 28, 2014·The New England Journal of Medicine·Amy G EganCurtis Rosebraugh

❮ Previous
Next ❯

Citations

May 19, 2020·Diabetic Medicine : a Journal of the British Diabetic Association·S T RønneS M Hemmingsen Arnfred
Jun 22, 2021·Diabetic Medicine : a Journal of the British Diabetic Association·Vicki ZabellSidse M Arnfred

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.